RASI, GUIDO
RASI, GUIDO
Dipartimento di Medicina Sperimentale
[Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).]
2021-11-01 Jommi, C; Armeni, P; Costa, F; Alberti, C; Bandello, F; Bordonaro, R; Caprodossi, A; Di Maio, M; Gaudioso, A; Giuliani, G; Langella, R; Marata, Am; Patarnello, F; Pinto, C; Rasi, G; Villa, F
A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP) - A possible new tumor marker
1996-01-01 Garaci, E; Sinibaldi, P; Rasi, G
A new tumour associated antigen of non-small cell lung cancer: Tumour Liberated Proteins (TLP) - A possible new tumor marker
1996-01-01 Garaci, E; Sinibaldi, P; Rasi, G
A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems
2022-01-01 Xoxi, E; Rumi, F; Kanavos, P; Dauben, H; Gutierrez-Ibarluzea, I; Wong, O; Rasi, G; Cicchetti, A
Access to patient-level trial data--a boon to drug developers
2013-10-24 Eichler, H; Pétavy, F; Pignatti, F; Rasi, G
ACTIVATION OF HUMAN ENDOGENOUS RETROVIRUS-K AND PRODUCTION OF INFECTIOUS VIRUS-LIKE PARTICLES IN HUMAN MELANOMA CELLS ABS -0153
2006-01-01 Serafino, A; Balestrieri, E; Pierimarchi, P; Matteucci, C; Rasi, G; Moroni, G; Mastino, A; Garaci, E; SINIBALDI VALLEBONA, P
Added therapeutic benefit and drug licensing
2019-09-01 Eichler, H; Enzmann, H; Rasi, G
An audience with Guido Rasi. Interview by Asher Mullard
2012-03-01 Rasi, G
Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling
2012-06-01 Serafino, A; Moroni, N; Psaila, R; Zonfrillo, M; Andreola, F; Wannenes, F; Mercuri, L; Rasi, G; Pierimarchi, P
Anti-tumour immunogens and vaccines
2005-01-01 Rasi, G; Garaci, E; SINIBALDI VALLEBONA, P; Fazio, V; Rinaldi, M
ANTITUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA-1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL-CANCER IN RATS
1994-01-01 Rasi, G; Silecchia, G; SINIBALDI VALLEBONA, P; Spaziani, E; Pierimarchi, P; Sivilia, M; Tremiterra, S; Garaci, E
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
2020-04-01 Eichler, H; Koenig, F; Arlett, P; Enzmann, H; Humphreys, A; Pétavy, F; Schwarzer-Daum, B; Sepodes, B; Vamvakas, S; Rasi, G
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
2020-01-01 Eichler, H-; Koenig, F; Arlett, P; Enzmann, H; Humphreys, A; Petavy, F; Schwarzer-Daum, B; Sepodes, B; Vamvakas, S; Rasi, G
Asthma, allergy and the olympics: A 12-year survey in elite athletes
2015-01-01 Bonini, M; Gramiccioni, C; Fioretti, D; Ruckert, B; Rinaldi, M; Akdis, C; Todaro, A; Palange, P; Carlsen, K-; Pelliccia, A; Rasi, G; Bonini, S; Aida,
Big Data – How to Realize the Promise
2020-01-01 Cave, A; Brun, Nc; Sweeney, F; Rasi, G; Senderovitz, T
BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS
1994-01-01 Lopez, M; Carpano, S; Cavaliere, R; Dilauro, L; Ameglio, F; Vitelli, G; Frasca, A; Vici, P; Pignatti, F; Rosselli, M; Rasi, G; Garaci, E
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union
2014-03-15 Pignatti, F; Ehmann, F; Hemmings, R; Jonsson, B; Nuebling, M; Papaluca Amati, M; Posch, M; Rasi, G
Characterization of four newly established melanoma cell lines
1992-01-01 Melino, G; SINIBALDI VALLEBONA, P; Spagnoli, L; Vernole, P; Rasi, G; D'Atri, S; Tartaglia, L; Catani, Mv; Annichiarico Petruzzelli, M; Finazzi Agrò, A; Garaci, E
Characterization of three melanoma cell lines (TVM-A12, TVM-A-197, TVM-BO): Sensitivity to lysis and effect of retinoic acid
1993-01-01 Melino, G; Sinibaldi-Vallebona, P; D'Atri, S; Annicchiarico-Petruzzelli, M; Rasi, G; Catani, Mv; Tartaglia, Rl; Vernole, P; Spagnoli, Lg; Finazzi-Agro, A; Garaci, E
Clinical trial publications: A sufficient basis for healthcare decisions?
2020-01-01 Eichler, H-; Rasi, G
| Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
|---|---|---|---|---|
| 1-nov-2021 | [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).] | Jommi, C; Armeni, P; Costa, F; Alberti, C; Bandello, F; Bordonaro, R; Caprodossi, A; Di Maio, M; Gaudioso, A; Giuliani, G; Langella, R; Marata, Am; Patarnello, F; Pinto, C; Rasi, G; Villa, F | Articolo su rivista | |
| 1-gen-1996 | A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP) - A possible new tumor marker | Garaci, E; Sinibaldi, P; Rasi, G | Articolo su rivista | |
| 1-gen-1996 | A new tumour associated antigen of non-small cell lung cancer: Tumour Liberated Proteins (TLP) - A possible new tumor marker | Garaci, E; Sinibaldi, P; Rasi, G | Articolo su rivista | |
| 1-gen-2022 | A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems | Xoxi, E; Rumi, F; Kanavos, P; Dauben, H; Gutierrez-Ibarluzea, I; Wong, O; Rasi, G; Cicchetti, A | Articolo su rivista | |
| 24-ott-2013 | Access to patient-level trial data--a boon to drug developers | Eichler, H; Pétavy, F; Pignatti, F; Rasi, G | Articolo su rivista | |
| 1-gen-2006 | ACTIVATION OF HUMAN ENDOGENOUS RETROVIRUS-K AND PRODUCTION OF INFECTIOUS VIRUS-LIKE PARTICLES IN HUMAN MELANOMA CELLS ABS -0153 | Serafino, A; Balestrieri, E; Pierimarchi, P; Matteucci, C; Rasi, G; Moroni, G; Mastino, A; Garaci, E; SINIBALDI VALLEBONA, P | Intervento a convegno | |
| 1-set-2019 | Added therapeutic benefit and drug licensing | Eichler, H; Enzmann, H; Rasi, G | Articolo su rivista | |
| 1-mar-2012 | An audience with Guido Rasi. Interview by Asher Mullard | Rasi, G | Articolo su rivista | |
| 1-giu-2012 | Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling | Serafino, A; Moroni, N; Psaila, R; Zonfrillo, M; Andreola, F; Wannenes, F; Mercuri, L; Rasi, G; Pierimarchi, P | Articolo su rivista | |
| 1-gen-2005 | Anti-tumour immunogens and vaccines | Rasi, G; Garaci, E; SINIBALDI VALLEBONA, P; Fazio, V; Rinaldi, M | Brevetti | |
| 1-gen-1994 | ANTITUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA-1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL-CANCER IN RATS | Rasi, G; Silecchia, G; SINIBALDI VALLEBONA, P; Spaziani, E; Pierimarchi, P; Sivilia, M; Tremiterra, S; Garaci, E | Articolo su rivista | |
| 1-apr-2020 | Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation | Eichler, H; Koenig, F; Arlett, P; Enzmann, H; Humphreys, A; Pétavy, F; Schwarzer-Daum, B; Sepodes, B; Vamvakas, S; Rasi, G | Articolo su rivista | |
| 1-gen-2020 | Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation | Eichler, H-; Koenig, F; Arlett, P; Enzmann, H; Humphreys, A; Petavy, F; Schwarzer-Daum, B; Sepodes, B; Vamvakas, S; Rasi, G | Articolo su rivista | |
| 1-gen-2015 | Asthma, allergy and the olympics: A 12-year survey in elite athletes | Bonini, M; Gramiccioni, C; Fioretti, D; Ruckert, B; Rinaldi, M; Akdis, C; Todaro, A; Palange, P; Carlsen, K-; Pelliccia, A; Rasi, G; Bonini, S; Aida, | Articolo su rivista | |
| 1-gen-2020 | Big Data – How to Realize the Promise | Cave, A; Brun, Nc; Sweeney, F; Rasi, G; Senderovitz, T | Articolo su rivista | |
| 1-gen-1994 | BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS | Lopez, M; Carpano, S; Cavaliere, R; Dilauro, L; Ameglio, F; Vitelli, G; Frasca, A; Vici, P; Pignatti, F; Rosselli, M; Rasi, G; Garaci, E | Articolo su rivista | |
| 15-mar-2014 | Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union | Pignatti, F; Ehmann, F; Hemmings, R; Jonsson, B; Nuebling, M; Papaluca Amati, M; Posch, M; Rasi, G | Articolo su rivista | |
| 1-gen-1992 | Characterization of four newly established melanoma cell lines | Melino, G; SINIBALDI VALLEBONA, P; Spagnoli, L; Vernole, P; Rasi, G; D'Atri, S; Tartaglia, L; Catani, Mv; Annichiarico Petruzzelli, M; Finazzi Agrò, A; Garaci, E | Articolo su rivista | |
| 1-gen-1993 | Characterization of three melanoma cell lines (TVM-A12, TVM-A-197, TVM-BO): Sensitivity to lysis and effect of retinoic acid | Melino, G; Sinibaldi-Vallebona, P; D'Atri, S; Annicchiarico-Petruzzelli, M; Rasi, G; Catani, Mv; Tartaglia, Rl; Vernole, P; Spagnoli, Lg; Finazzi-Agro, A; Garaci, E | Articolo su rivista | |
| 1-gen-2020 | Clinical trial publications: A sufficient basis for healthcare decisions? | Eichler, H-; Rasi, G | Articolo su rivista |